Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing (Q39835258)

15 September 2017

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing (English)

1 reference

15 September 2017

0 references

1 reference

T R Wilson

1

1 reference

15 September 2017

K M Redmond

2

1 reference

15 September 2017

K M McLaughlin

3

1 reference

15 September 2017

N Crawford

4

1 reference

15 September 2017

K Gately

5

1 reference

15 September 2017

K O'Byrne

6

1 reference

15 September 2017

C Le-Clorrenec

7

1 reference

15 September 2017

C Holohan

8

1 reference

15 September 2017

D A Fennell

9

1 reference

15 September 2017

P G Johnston

10

1 reference

15 September 2017

D B Longley

11

1 reference

15 September 2017

19 June 2009

1 reference

Cell Death & Differentiation

15 September 2017

1 reference

15 September 2017

16

1 reference

15 September 2017

10

1 reference

15 September 2017

1352-1361

1 reference

https://scigraph.springernature.com/pub.10.1038/cdd.2009.76

15 September 2017

0 references

cites work

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inh

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Role and prognostic significance of tumor necrosis factor‐related apoptosis‐inducing ligand death receptor DR5 in nonsmall‐cell lung cancer and precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Increased apoptosis in metastatic human colonic adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Two CD95 (APO-1/Fas) signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

c-FLIP: a key regulator of colorectal cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

c-FLIP inhibits chemotherapy-induced colorectal cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

A novel receptor for Apo2L/TRAIL contains a truncated death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Ceramide-mediated clustering is required for CD95-DISC formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

7 January 2021

Increased expression of cFLIP(L) in colonic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

7 January 2021

Differential inactivation of caspase-8 in lung cancers.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

7 January 2021

A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2009.76

7 January 2021

Identifiers

DOI

10.1038/CDD.2009.76

1 reference

Dimensions Publication ID

15 September 2017

0 references

1 reference